IL144989A0 - Method for acylating peptides and novel acylating agents - Google Patents

Method for acylating peptides and novel acylating agents

Info

Publication number
IL144989A0
IL144989A0 IL14498900A IL14498900A IL144989A0 IL 144989 A0 IL144989 A0 IL 144989A0 IL 14498900 A IL14498900 A IL 14498900A IL 14498900 A IL14498900 A IL 14498900A IL 144989 A0 IL144989 A0 IL 144989A0
Authority
IL
Israel
Prior art keywords
acylating
peptides
novel
agents
acylating agents
Prior art date
Application number
IL14498900A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL144989A0 publication Critical patent/IL144989A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL14498900A 1999-03-17 2000-03-16 Method for acylating peptides and novel acylating agents IL144989A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99610019 1999-03-17
EP00910573A EP1163211B1 (en) 1999-03-17 2000-03-16 Method for acylating peptides and proteins
PCT/DK2000/000117 WO2000055119A1 (en) 1999-03-17 2000-03-16 Method for acylating peptides and novel acylating agents

Publications (1)

Publication Number Publication Date
IL144989A0 true IL144989A0 (en) 2002-06-30

Family

ID=26074622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14498900A IL144989A0 (en) 1999-03-17 2000-03-16 Method for acylating peptides and novel acylating agents

Country Status (16)

Country Link
EP (2) EP1163211B1 (cs)
CN (1) CN1344248A (cs)
AT (1) ATE409193T1 (cs)
AU (1) AU3273500A (cs)
BR (1) BR0009040A (cs)
CA (1) CA2361830A1 (cs)
CZ (1) CZ20013018A3 (cs)
DE (1) DE60040333D1 (cs)
ES (1) ES2315226T3 (cs)
HU (1) HUP0200297A3 (cs)
IL (1) IL144989A0 (cs)
NO (1) NO20014508L (cs)
PL (1) PL351326A1 (cs)
RU (1) RU2001128068A (cs)
WO (1) WO2000055119A1 (cs)
ZA (1) ZA200106884B (cs)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
ATE411337T1 (de) * 2001-07-24 2008-10-15 Novo Nordisk As Verfahren zur herstellung acylierter polypeptide
JP2005503141A (ja) * 2001-07-24 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ アシル化ポリペプチドを作出するための方法
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP1546090B1 (en) * 2002-09-25 2009-06-24 Novo Nordisk A/S Method for producing acylated peptides
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004029081A2 (en) * 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
EP2280993A1 (en) 2008-05-15 2011-02-09 Novo Nordisk A/S Purification of peptides prepared by solid phase synthesis
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
TW201326194A (zh) 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
IN2014MN02304A (cs) 2012-05-03 2015-08-07 Zealand Pharma As
IN2015DN00544A (cs) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
JP6475233B2 (ja) 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
EP3016975B1 (en) 2013-07-04 2019-01-16 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN104558097A (zh) * 2014-05-20 2015-04-29 广东东阳光药业有限公司 肽的酰化方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017127007A1 (en) 2016-01-20 2017-07-27 Poypeptide Laboratories Holding (Ppl) Ab METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3196206A1 (en) 2016-01-20 2017-07-26 Lonza Ltd Method for preparation of liraglutide
EP3205660A1 (en) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of peptides with pswang linker
EP3205664A1 (en) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of liraglutide using bal linker
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
MX388822B (es) 2016-12-05 2025-03-20 Nuritas Ltd Composiciones que comprenden peptido wkdeagkplvk.
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN111909073A (zh) * 2019-05-10 2020-11-10 江苏万邦医药科技有限公司 一种制备高纯度脂肪酸衍生物的方法
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022537318A (ja) 2019-06-17 2022-08-25 バイオマルク ファーマシューティカルズ リミテッド ぶどう膜炎の処置におけるペプチド及びその使用の方法
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
BR112022003760A2 (pt) 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos
PH12022550510A1 (en) 2019-09-03 2023-09-04 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
US20230129788A1 (en) 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4281039A2 (en) 2021-01-25 2023-11-29 Mylan Ireland Limited Pharmaceutical glp peptide compositions and methods of preparation thereof
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
JP2024533153A (ja) 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム
IL319599A (en) 2022-09-19 2025-05-01 Zealand Pharma As Combination therapy
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
TW202504913A (zh) 2023-06-21 2025-02-01 丹麥商西蘭製藥公司 減重
MX2025015167A (es) 2023-06-21 2026-02-03 Zealand Pharma As Analogos con propiedades mejoradas
TW202517291A (zh) 2023-06-30 2025-05-01 丹麥商西蘭製藥公司 組合療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP0929576A1 (en) * 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン

Also Published As

Publication number Publication date
HUP0200297A3 (en) 2002-09-30
NO20014508D0 (no) 2001-09-17
PL351326A1 (en) 2003-04-07
EP1956000A1 (en) 2008-08-13
HUP0200297A2 (en) 2002-06-29
AU3273500A (en) 2000-10-04
DE60040333D1 (de) 2008-11-06
EP1163211B1 (en) 2008-09-24
CZ20013018A3 (cs) 2002-02-13
CN1344248A (zh) 2002-04-10
CA2361830A1 (en) 2000-09-21
EP1956000B1 (en) 2016-10-05
WO2000055119A1 (en) 2000-09-21
NO20014508L (no) 2001-09-17
ES2315226T3 (es) 2009-04-01
ZA200106884B (en) 2002-03-01
EP1163211A1 (en) 2001-12-19
ATE409193T1 (de) 2008-10-15
RU2001128068A (ru) 2004-02-20
BR0009040A (pt) 2001-12-18

Similar Documents

Publication Publication Date Title
PL351326A1 (en) Method for acylating peptides and novel acylating agents
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
DE69532996D1 (de) Peptidanaloge des menschlichen basischen myelinproteins
GR3019901T3 (en) Osteoinductive pharmaceutical formulations
IL134699A0 (en) Protein composition and process for isolating a protein composition from a muscle source
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU1232602A (en) Vaccine composition
ID19203A (id) Proses untuk mengisolasi komposisi protein dari sumber otot dan komposisi protein tersebut
ZA9811327B (en) Compositions and methods for altering amino acid content of proteins
EP0966297A4 (en) METHODS OF REGULATING GASTROINTESTINAL MOTILITY
HU9200548D0 (en) Improved activity process of recombined proteins
IL85020A0 (en) Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
GB9606040D0 (en) Active peptide
IL95863A0 (en) Anticoagulant peptides and compositions containing them
IL153600A0 (en) TRANSPORT OF PEPTIDES AMONG WHICH C-TERMINAL Erns PEPTIDE AND ANALOGUES THEREOF
DE3852105D1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
NZ511747A (en) Regulatory/unfolding peptides of ezrin
ATE282088T1 (de) Aminopeptidase, welche von bacillus licheniformis abstammt und verfahren zur herstellung von proteinen des natürlichen typs
SI0888286T1 (en) Novel substituted cyclic amino acids as pharmaceutical agents
TH17162A (th) สารผสมฟอกจากที่ประกอบด้วยเอนไซม์โพรทีเอส
MX9708930A (es) Alteracion de composiciones aminoacidas en semillas.